Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many Medicines and Healthcare products Regulatory Agency Yellow Card reports on over‑the‑counter cough and cold medicines were received in each of the last five years.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) publishes information in the form of interactive Drug Analysis Profiles which can be accessed here on the Yellow Card website, at the following link:
https://yellowcard.mhra.gov.uk/idaps
You will be able to access a complete listing of all suspected adverse drug reactions that have been reported to the MHRA via the Yellow Card scheme for all medicines, including medicines used to treat coughs and colds. This includes all reports received from healthcare professionals, members of the public, and pharmaceutical companies.
Please note information regarding whether a drug was prescribed or purchased over the counter is not mandatory to provide on a Yellow Card and as such we do not capture this information in a structured data field to be able to provide as part of this request.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with his international counterparts on the relevance of the UN Convention on the Rights of Persons with Disabilities to individuals harmed by sodium valproate.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care, has not had specific discussions with international counterparts regarding the relevance of the UN Convention on the Rights of Persons with Disabilities to individuals harmed by sodium valproate. Our focus remains on improving the safety of sodium valproate, so it is not used for women or girls of childbearing potential unless a pregnancy prevention plan is in place and other treatments are ineffective or not tolerated. The Government is also carefully considering the recommendations made by the Patient Safety Commissioner in The Hughes Report, which sets out options for redress for those harmed by valproate.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the feasibility of establishing a dedicated, no-fault compensation scheme for individuals harmed by sodium valproate exposure, in the context of the recommendations of the Independent Medicines and Medical Devices Safety Review (2020).
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not yet undertaken an assessment of the feasibility of establishing a dedicated, no-fault compensation scheme for individuals harmed by sodium valproate exposure, in the context of the recommendations of the Independent Medicines and Medical Devices Safety Review (IMMDS).
The previous administration accepted seven of the nine recommendations of the IMMDS Review, whether in full, in part, or in principle, including issuing an unreserved apology on behalf of the healthcare system, appointing Dr Henrietta Hughes as the first Patient Safety Commissioner for England, and establishing nine specialist mesh centres now operating across the country.
This is a complex, cross-Government policy area involving multiple organisations. As set out in the Hughes Report, the Government is carefully considering the Patient Safety Commissioner’s recommendations, including the proposed approaches to redress for those harmed by sodium valproate. This work requires coordinated input from several departments, and we will provide a further update in due course.
I met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and made clear that the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Government records deaths where harm caused by sodium valproate exposure is listed as a contributing factor.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Office for National Statistics (ONS) collects and publishes mortality statistics for deaths registered in England and Wales. Deaths in which harm caused by sodium valproate exposure is a contributing factor are not captured as a distinct, searchable category in ONS mortality statistics. Further information on mortality statistics is available on the ONS website, at the following link:
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment is made of level of need for unmet trauma interventions for offenders (a) in prison and (b) on probation; and how these needs are being met.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No assessment has been made of the level of need for unmet trauma interventions for offenders in prison and on probation, or how these needs are being met.
NHS England commissions healthcare services in every prison in England to a level equivalent to community provision. The National Integrated Prison Mental Health Service Specification requires trauma‑informed care as a core part of mental health support, with teams equipped to recognise and respond to the effects of trauma through assessment, screening, care planning, risk management, and evidence‑based interventions.
NHS England is reviewing the National Integrated Prison Mental Health Service Specification to ensure it continues to meet the needs of the prison population.
Asked by: Mark Hendrick (Labour (Co-op) - Preston)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding his Department has allocated to genomic testing in Lancashire for the (a) 2026-27 (b) 2027-28 and (c) 2028-29 financial years.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England is responsible for commissioning the NHS Genomic Medicine Service (GMS) for patients in the National Health Service in England. Genomic testing is currently delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). This includes the North West NHS GLH, which delivers genomic testing for patients in the North West of England, including those in the Lancashire Teaching Hospitals NHS Foundation Trust. NHS England has undertaken a procurement of the NHS GMS lead providers for services to be delivered from 1 April 2026, including genomic testing. The 2026/27 contract, that will include the financial value for the NHS GMS lead providers, will be complete by Quarter four of 2025/26. Financial values for subsequent years are to be agreed on an annual basis thereafter.
Asked by: Matt Vickers (Conservative - Stockton West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress he has made in improving access to kidney transplantation, including reducing waiting times and increasing rates of living and deceased organ donation.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS Blood and Transplant (NHSBT) is the organisation responsible for organ donation services in the United Kingdom. Figures on the number of patients active on the kidney transplant waiting list and median waiting times are available at the following link:
https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/36811/section-5-kidney-activity.pdf
The Department, along with NHSBT, continues to take action to improve access to kidney transplantation. This includes high profile, year-round campaigns including Living Donation Week, Organ Donation Week, and World Kidney Day, and partnerships with charities and community groups to promote living donation, the UK Living Kidney Sharing Scheme (UKLKSS) and the importance of declaring wishes on the Organ Donation Register (ODR). In addition, the Living Donor Futures programme, launching this early this year, will look at how NHSBT can support the growth of living donor programmes locally and within the UKLKSS. Further information on the UKLKSS is available at the following link:
https://www.odt.nhs.uk/living-donation/uk-living-kidney-sharing-scheme/;
The Department-led Implementation Steering Group for Organ Utilisation is working to maximise the potential for organ transplantation, aiming to reduce waiting times and improve access. This includes the initiation of a national programme of Assessment and Recovery Centres (ARCs) by NHSBT, which will utilise innovation to enhance the assessment, evaluation, and utilisation of donor organs. Pilot ARCs are set to begin in early 2026. Further information on the Implementation Steering Group for Organ Utilisation is available at the following link:
https://www.odt.nhs.uk/odt-structures-and-standards/clinical-leadership/implementation-steering-group-for-organ-utilisation/
Additionally, the Organ Donation Joint Working Group recently published recommendations to improve organ donation consent rates, increase societal action for organ donation, and increase the pool of potential donors in their report this January. The recommendations are available at the following link:
https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/38066/odjwg-report.pdf
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of reinstating the annual health check target of 75% for people with learning disabilities.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department and NHS England have not undertaken a specific assessment of reinstating the 75% annual health check target for people with a learning disability. My Rt Hon. Friend, the Secretary of State for Health and Social Care, wrote to general practitioners (GPs) in October 2025 emphasising the importance of the learning disability register and providing high quality annual health checks. These checks are the first line of defence for people with a learning disability, many of whom live with additional health needs, including long-term conditions. Strong support from GPs to maintain learning disability annual health checks has enabled more people than ever before to receive a health check and health action plan, an increase of more than 20% since 2020.
As of March 2025, 81.5% of eligible people on the GP learning disability register received an annual health check, surpassing the previous 75% National Health Service target.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has undertaken of the potential impact of Medicines and Healthcare products Regulatory Agency winter wellness campaigns during the last five years.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The main Government health winter campaigns are run by the UK Health Security Agency and NHS England, which the Medicines and Healthcare products Regulatory Agency (MHRA) supports.
The MHRA also runs annual winter campaigns to raise public awareness of medicines and medical devices safety that achieves media coverage and social media engagement.
For example, the MHRA’s 2025/26 campaign provided five public safety tips covering medicines and medical devices. It achieved media coverage in national print and online, regional and trade press, as well as an interview on BBC One Breakfast.
The MHRA created and posted social media content throughout this period which was seen approximately 50,000 times. The MHRA also worked with key stakeholders, such as the National Fire Chiefs Council, to help amplify safety messages.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he has taken to ensure that people who have brought forward cases relating to the unsafe prescription of sodium valproate are not denied access to justice due to their (a) cases being complex and (b) disability.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS Resolution (NHSR) is the body that manages clinical negligence and other claims against the National Health Service in England, and a full list of their clinical schemes can be found at the following link:
https://resolution.nhs.uk/services/claims-management/clinical-schemes/
NHSR has published in their most recent Annual Report and Accounts, for 2024/25, that they offer simplified processes for vaginal mesh claims and sodium valproate claims to be reported to them by unrepresented claimants. They refer to these simplified processes as gateways. Further details can be found on page 41 of their NHS Resolution Annual report and accounts 2024/25, at the following link:
https://resolution.nhs.uk/wp-content/uploads/2025/07/NHS-Resolution-ARA-24-25_ACCESSIBLE.pdf